J&J Topamax Approved For Migraine Prevention In Twice-Daily Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
The supplemental indication for topiramate clears FDA. The recommended twice-daily dose for migraine prevention may place Topamax at a disadvantage to Abbott’s once-daily dosing for Depakote ER.
You may also be interested in...
Topamax Launch For Migraine Prevention Includes Unbranded DTC Ad
Rollout of Ortho-McNeil's disease awareness ad coincides with sales force launch meeting for the new indication. The ad directs patients to a toll-free phone number and a website.
Topamax Launch For Migraine Prevention Includes Unbranded DTC Ad
Rollout of Ortho-McNeil's disease awareness ad coincides with sales force launch meeting for the new indication. The ad directs patients to a toll-free phone number and a website.
J&J Is Spitzer's Next Target: New York AG Opens Broad Off-Label Promotion Investigation
Procrit, Risperdal and four other leading J&J pharmaceutical brands are the subject of a document request from New York Attorney General Eliot Spitzer. J&J is already facing two federal investigations into marketing practices.